Streetbeat News

KHTRF

Knight Therapeutics Inc

https://www.gud-knight.com/

CEO

Jonathan Goodman

Industry

Pharmaceutical Preparation Manufacturing

Open

3.67

Mkt cap

371M

Volume

525

High

3.69

P/E Ratio

-17.55

52-wk high

4.55

Low

3.67

Div yield

N/A

52-wk low

3.65

Knight Therapeutics Inc. (KHTRF) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Samira Sakhia and CFO Arvind Utchanah.

Portfolio Pulse from

November 09, 2024 | 12:00 pm

Raymond James analyst David Novak has maintained an Outperform rating on Knight Therapeutics (OTC:KHTRF) and raised the price target from $7 to $7.5.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 5:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.